Best Nanoknife Doctors Abroad for Australian Patients

Dr. Son Dong-wan specializes in urologic oncology, urinary incontinence, and sexual dysfunction. He performs laser prostate surgery. He provides robotic and laparoscopic treatment for cancers of the prostate, bladder, ureter, and kidney. He also treats ureteropelvic junction obstruction.

His minimally invasive practice includes laparoscopic nephrectomy and prostatectomy. He performs cystoscopic TURBT and TURP. He offers ureteroscopic laser stone removal and percutaneous nephrolithotomy. He treats BPH, prostatitis, urinary stones, testicular cancer, stress urinary incontinence (SUI), overactive bladder (OAB), and male infertility.

Dr. Mustafa Solak is a clinical oncologist at Hisar Hospital Intercontinental in Istanbul. He completed a fellowship at the prestigious Hacettepe University Cancer Institute. Dr. Solak previously practiced at The University of Texas MD Anderson Cancer Center. He treats a variety of complex cancers, including lung, breast, and gastrointestinal malignancies.

• Specializes in the treatment of testicular, ovarian, and head and neck cancers.
• Performs oncology procedures including chemotherapy, immunotherapy, and targeted therapy.
• Trained at Hacettepe University and Istanbul Sisli Etfal Training Hospital.
• Practices at a JCI-accredited facility that treats over 500,000 patients annually.

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

The doctor is an oncologist specializing in the treatment of breast, lung, and gastrointestinal cancers. Currently, the doctor practices at Istinye Liv University Hospital.

With a career spanning multiple esteemed institutions, the doctor has served as an Internal Medicine Specialist at Malatya State Hospital, a physician at Ankara Oncology Clinic, and a member of the Oncology Department at Erzurum Regional Training and Research Hospital.

The doctor graduated from the Faculty of Medicine at Selcuk University and achieved the title of Associate Professor in 2016.